There's no compound called 1,1-cyclopropanedicarboxylate because it's chemically impossible. Here's why:
* **Cyclopropane:** This is a three-carbon ring structure. Each carbon in the ring needs to be bonded to two other carbon atoms to form the closed ring.
* **Carboxylate:** This functional group (-COO-) is attached to a carbon atom.
* **1,1-** This indicates two substituents are attached to the same carbon atom.
The problem arises when trying to combine these elements:
* You cannot have two carboxylate groups attached to the same carbon atom in a cyclopropane ring. This would violate the valency rules of carbon (carbon can only form four bonds).
**What Might be the Intended Compound?**
It's likely there's a typo or misunderstanding in the compound's name. Some possibilities include:
* **1,1-Cyclopropanedicarboxylate:** This would be the anion form of 1,1-cyclopropanedicarboxylic acid. This compound exists and can be synthesized, but it's not commonly studied.
* **1,2-Cyclopropanedicarboxylate:** This is a common diacid and its salts. It's an important intermediate in organic synthesis and has potential applications in the development of new drugs and materials.
**Importance in Research**
While 1,1-cyclopropanedicarboxylate doesn't exist, cyclopropane-based compounds are often used in research due to:
* **Strain:** The small ring size of cyclopropane creates significant ring strain, leading to unique reactivity.
* **Chirality:** Some cyclopropane derivatives can be chiral, which is important for developing enantioselective reactions and pharmaceuticals.
* **Bioactivity:** Cyclopropane rings are found in some natural products and synthetic drugs, demonstrating their potential biological activity.
If you can provide more context or the intended compound, I can provide a more specific answer regarding its importance in research.
cyclopropane-1,1-dicarboxylic acid: inhibits 1-aminocyclopropane-1-carboxylic acid oxidase; structure in first source
ID Source | ID |
---|---|
PubMed CID | 69017 |
CHEMBL ID | 1993862 |
SCHEMBL ID | 106415 |
MeSH ID | M0188869 |
Synonym |
---|
AC-1893 |
nsc-626865 |
NCI60_008490 |
1,1-cyclopropanedicarboxylic acid |
cyclopropane-1,1-dicarboxylic acid |
nsc626865 |
cyclopropane-1,1-dicarboxylic acid, 97% |
1,1-cyclopropanedicarboxylate |
598-10-7 |
cyclopropane, 3 |
bdbm82142 |
A8394 |
cyclopropane-1,1-dicarboxylicacid |
einecs 209-917-2 |
cyclopropanedicarboxylic acid |
FT-0606081 |
AM20100460 |
AKOS009158920 |
cyclopropane 1,1-dicarboxylic acid |
SCHEMBL106415 |
PS-5731 |
CHEMBL1993862 |
W-105298 |
cycloprpopane-1,1-dicarboxylic acid |
ethylenemalonic acid |
vinyl-malonic acid |
propene-3,3-dicarboxylic acid |
vinaconic acid |
DTXSID20208526 |
mfcd00013727 |
CS-W002094 |
9ty , |
Z877371762 |
BCP26949 |
SY014841 |
trans-cyclopropanedicarboxylic acid |
EN300-58851 |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
isoleucine biosynthetic process | Ketol-acid reductoisomerase (NADP(+)) | Escherichia coli K-12 |
valine biosynthetic process | Ketol-acid reductoisomerase (NADP(+)) | Escherichia coli K-12 |
pantothenate biosynthetic process | Ketol-acid reductoisomerase (NADP(+)) | Escherichia coli K-12 |
amino acid biosynthetic process | Ketol-acid reductoisomerase (NADP(+)) | Escherichia coli K-12 |
branched-chain amino acid biosynthetic process | Ketol-acid reductoisomerase (NADP(+)) | Escherichia coli K-12 |
isoleucine biosynthetic process | Ketol-acid reductoisomerase (NADP(+)) | Escherichia coli K-12 |
valine biosynthetic process | Ketol-acid reductoisomerase (NADP(+)) | Escherichia coli K-12 |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
magnesium ion binding | Ketol-acid reductoisomerase (NADP(+)) | Escherichia coli K-12 |
ketol-acid reductoisomerase activity | Ketol-acid reductoisomerase (NADP(+)) | Escherichia coli K-12 |
2-dehydropantoate 2-reductase activity | Ketol-acid reductoisomerase (NADP(+)) | Escherichia coli K-12 |
oxidoreductase activity | Ketol-acid reductoisomerase (NADP(+)) | Escherichia coli K-12 |
oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | Ketol-acid reductoisomerase (NADP(+)) | Escherichia coli K-12 |
identical protein binding | Ketol-acid reductoisomerase (NADP(+)) | Escherichia coli K-12 |
metal ion binding | Ketol-acid reductoisomerase (NADP(+)) | Escherichia coli K-12 |
NADP binding | Ketol-acid reductoisomerase (NADP(+)) | Escherichia coli K-12 |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
cytoplasm | Ketol-acid reductoisomerase (NADP(+)) | Escherichia coli K-12 |
cytosol | Ketol-acid reductoisomerase (NADP(+)) | Escherichia coli K-12 |
protein-containing complex | Ketol-acid reductoisomerase (NADP(+)) | Escherichia coli K-12 |
cytosol | Ketol-acid reductoisomerase (NADP(+)) | Escherichia coli K-12 |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1799596 | Enzyme Inhibition Assay from Article 10.1111/j.1747-0285.2009.00924.x: \\High throughput receptor-based virtual screening under ZINC database, synthesis, and biological evaluation of ketol-acid reductoisomerase inhibitors.\\ | 2010 | Chemical biology & drug design, Feb, Volume: 75, Issue:2 | High throughput receptor-based virtual screening under ZINC database, synthesis, and biological evaluation of ketol-acid reductoisomerase inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (9.09) | 18.2507 |
2000's | 5 (45.45) | 29.6817 |
2010's | 3 (27.27) | 24.3611 |
2020's | 2 (18.18) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.18) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 12 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |